Back to Peptides

Survodutide

Metabolic & Weight Loss

Survodutide is an investigational dual GLP-1/glucagon receptor agonist developed for obesity, MASH (Metabolic Associated Steatohepatitis), and cirrhosis. It promotes significant weight loss, improves liver markers, reduces visceral adiposity, and increases energy expenditure. Human trials report robust reductions in body weight and promising outcomes in liver disease settings. Developed by Boehringer Ingelheim, it is currently in clinical trials.

Reconstitute
2 mL BAC + 3mg vial
15 mcg/unit
Daily Range
0.6–4.8 mg Subcutaneous (SQ)
Weekly
Standard Dose
2.4 mg
Cycle
4–8 weeks
then reassess
SurvodutideGLP-1glucagon receptor agonistweight lossliver cirrhosisMASH

Dosing & Reconstitution Guide

In trials, doses range from 1.5–6.0 mg weekly. These regimens are investigational and not for use outside clinical studies.

Standard / Gradual Approach

standard
PhaseDoseVolume
Week 10.5mg
Week 51mg
Week 91.5mg
Week 132.5mg

Protocol Summary

Subcutaneous (SQ): Weekly · Dose range 0.6–4.8 mg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending

Frequency & Cycling

SubQ Injection

Administer once weekly. Titrate starting from 0.6 mg to target dose (2.4–4.8 mg) over several weeks. Monitor body weight, liver function tests, and glycemic parameters. Continuous use protocol under practitioner supervision.

🧪 Quick Start

Potential Benefits & Use Cases

Survodutide is an investigational drug not approved for therapeutic use.
Achieves 12.5–14.9% weight loss (vs placebo) over 46 weeks (Phase 2)
Resolves MASH without fibrosis worsening in 47–62% of patients vs 14% placebo (Phase 2)
Reduces liver fat by ≥30% in 63–67% of patients (Phase 2)
Improves fibrosis by ≥1 stage in 34–36% vs 22% placebo (Phase 2)
Consistent efficacy across multiple randomized controlled trials (Phase 2)
Clinical data Strong preclinical Limited data

Mechanism of Action

→Dual agonist for GLP-1 and glucagon receptors
→Suppresses appetite and food intake
→Enhances energy expenditure and lipolysis
→Improves hepatic insulin sensitivity and glucose homeostasis

Lifestyle & Optimization

timing

Weekly injection. Consistent timing.

diet

Structured meal plan with adequate protein and healthy fats. Stay well-hydrated (2–3 liters daily). Monitor appetite and adjust caloric intake.

exercise

Exercise 4–5 times weekly combining cardio and resistance.

sleep

Adequate sleep for metabolic recovery.

Peptide Research & Preclinical Studies

Evidence-Based Research Findings

Study TitleType
The Lancet — Survodutide for MASH (Phase 2b)Reference
Boehringer Ingelheim — Survodutide pipeline overviewReference
ClinicalTrials.gov — NCT05813249: SYNCHRONIZE Phase 3 trialReference
Nature Medicine — GLP-1/glucagon dual receptor agonists for MASH and obesityReference

Side Effects & Safety

Common Side Effects

• Gradual titration mitigates GI tolerability issues

🧮 Dose Calculator

Concentration
15.0
mcg/unit
Draw Volume
33
units (0.330 mL)
For a 500 mcg dose, draw 33 units on a U-100 insulin syringe
🧬

Bioavailability & Absorption

SubQ Injection
High bioavailability suitable for weekly dosing.
Oral Administration
Low or insufficient bioavailability; not suitable for oral administration.
Half-Life
Supports once-weekly dosing; estimated half-life 4–6 days
Degradation
Metabolized hepatically and renally excreted
Tissue Specificity
Acts on liver, pancreas, adipose tissue, and CNS appetite-regulating centers
⚗️

Peptide Details

Molecular Weight
4000
Formula
C172H265N43O51
Sequence
Specific proprietary sequence related to GLP-1 and glucagon.
⚖️

Legal Status & Regulatory

RegionStatus
FDANot Approved
EUNot Approved
AustraliaNot Approved
CanadaNot Approved

Storage Instructions

Lyophilized (Powder)
Store pre-filled pens at 2-8°C before first use. After initial use, may store at room temperature (15-30°C) for up to 30 days. Never freeze. Protect from light.
Reconstituted (Mixed)
Refrigerate at 2–8°C after reconstitution. Use within 28 days.